10x Genomics (TXG) Fundamentals 2026 — Revenue Analysis | SniperIQ
10x Genomics (TXG) is a US-listed Healthcare company in Medical - Healthcare Information Services with a market capitalization of $6.1B, trading at $47.79 on the NASDAQ. This SniperIQ fundamentals page covers 10x Genomics's valuation, profitability (net margin -3.5%), revenue ($643M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is 10x Genomics's market cap?
10x Genomics (TXG) has a market capitalization of approximately $6.1B, trading at $47.79 on the NASDAQ. Market cap moves with the live share price.
What is 10x Genomics's P/E ratio?
10x Genomics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 7.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is 10x Genomics?
10x Genomics runs a net profit margin of -3.5%, a gross margin of 69.6%, and an operating margin of -6.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does 10x Genomics generate?
10x Genomics reported revenue of $643M for fiscal year 2025, with net income of -$44M and earnings per share (EPS) of -0.35. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does 10x Genomics pay a dividend?
10x Genomics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is 10x Genomics financially healthy?
10x Genomics carries a debt-to-equity ratio of 0.10x and a current ratio of 5.90x, with a market beta of 2.04. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is 10x Genomics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For 10x Genomics (TXG) the key facts are: market cap $6.1B, revenue $643M, 52-week range 11.16-47.82. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track 10x Genomics's full fundamentals live
Get 10x Genomics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.